Medullary thyroid gland carcinoma
MONDO:0015277A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.
Also known as: C cell carcinoma, MTC, carcinoma of parafollicular cell, carcinoma, C-cell, malignant, medullary carcinoma, medullary carcinoma of the thyroid, medullary carcinoma of the thyroid gland, medullary carcinoma of thyroid
2831 clinical trials for this condition and its sub-types, 42 tagged with Medullary thyroid gland carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Medullary thyroid gland carcinoma
-
Familial medullary thyroid carcinoma 23 trials
-
New drug tarlatamab takes on tough lung cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug zanzalintinib aims to shrink thyroid tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests the drug zanzalintinib given before surgery in 45 people with advanced thyroid cancer. The goal is to see if the drug can shrink tumors, making surgery more effective. Researchers will also monitor safety and side effects.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could Once-Daily radiation replace Twice-Daily for breast cancer recurrence?
Disease control Recruiting nowThis study is for women whose breast cancer has come back after initial breast-conserving surgery and whole breast radiation. The standard treatment after repeat surgery is radiation twice a day for 30 sessions. This trial tests whether giving radiation once a day for 15 sessions…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Phase 1/2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Custom mRNA vaccine takes on rare endocrine cancers
Disease control Recruiting nowThis early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in…
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New scan spots hidden thyroid tumors that resist standard treatment
Diagnosis Recruiting nowThis study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New PET scan agent aims to better detect rare tumors
Diagnosis Recruiting nowThis study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…
Phase 2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New decision aid empowers thyroid cancer patients to choose their care path
Knowledge-focused Recruiting nowThis study creates and tests a decision aid for people with medullary thyroid cancer and their caregivers. The tool helps them discuss with their doctors whether to start or stop drugs, join clinical trials, or continue active monitoring. About 120 participants, including patient…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study aims to create clearer cancer education for hispanic patients
Knowledge-focused Recruiting nowThis study will adapt educational materials about medullary thyroid cancer to be more culturally appropriate and easier to understand for Spanish-speaking Hispanic or Latino patients. Researchers will interview 40 participants, including patients and caregivers, to gather feedbac…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Massive registry study aims to unlock secrets of rare thyroid cancer
Knowledge-focused Recruiting nowThis study uses a large registry of 2030 people with medullary thyroid cancer to track how the disease develops and spreads. Researchers will collect medical records, genetic data, and patient surveys to better understand the cancer's natural history. The goal is to improve how a…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC